Behbahani Ali 4

What Happened

• Behbahani Ali, a director of Monte Rosa Therapeutics, was granted a derivative award for 25,800 shares on 2026-06-11. The filing reports acquisition at $0.00 (no cash paid at grant); this is a grant/award (code A), not a cash purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely filing).
• Security: derivative award covering 25,800 shares; reported consideration $0.00.
• Vesting: the award vests in full upon the earlier of (i) June 11, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction type: grant/award (A). This is not an exercise or sale—no immediate cash transaction or disposition reported.

Context

• This appears to be a time‑based equity grant to a director that will only vest if the director remains in service through the stated vesting condition. Such awards are common for aligning director incentives and do not indicate an immediate buy/sell signal to the market.